| Entry |
|
|---|
| Name |
Fluorouracil (JP17/USP/INN);
5-FU (TN);
Adrucil (TN);
Carac (TN);
Fluoroplex (TN) |
|---|
| Product |
|
|---|
| Generic |
FLUOROURACIL (A-S Medication Solutions), FLUOROURACIL (Accord Healthcare), FLUOROURACIL (Accord Healthcare), FLUOROURACIL (BluePoint Laboratories), FLUOROURACIL (BluePoint Laboratories), FLUOROURACIL (Fresenius Kabi USA), FLUOROURACIL (Fresenius Kabi USA), FLUOROURACIL (Fresenius Kabi USA), FLUOROURACIL (Fresenius Kabi USA), FLUOROURACIL (Fresenius Kabi USA), FLUOROURACIL (Fresenius Kabi USA), FLUOROURACIL (Gland Pharma Limited), FLUOROURACIL (Gland Pharma Limited), FLUOROURACIL (Ingenus Pharmaceuticals), FLUOROURACIL (Ingenus Pharmaceuticals), FLUOROURACIL (Mayne Pharma), FLUOROURACIL CREAM (Mylan Pharmaceuticals), FLUOROURACIL (Mylan Pharmaceuticals), FLUOROURACIL (Sagent Pharmaceuticals), FLUOROURACIL (Spear Dermatology Products), FLUOROURACIL (Spear Dermatology Products), FLUOROURACIL (Taro Pharmaceuticals U.S.A.), FLUOROURACIL (Taro Pharmaceuticals U.S.A.) |
|---|
| Formula |
C4H3FN2O2
|
|---|
| Exact mass |
130.0179
|
|---|
| Mol weight |
130.0772
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Antineoplastic
DG01958 Nucleic acid derivative, antineoplastic
DG01935 Fluoropyrimidine antineoplastic
DG01935 Fluoropyrimidine antineoplastic
DG02018 Antimetabolite
DG01958 Nucleic acid derivative, antineoplastic
DG01935 Fluoropyrimidine antineoplastic
Metabolizing enzyme substrate
DG02984 DPYD substrate
|
|---|
| Remark |
| Therapeutic category: | 4223 |
| Product (DG00687): | D00584<JP/US> |
|
|---|
| Efficacy |
Antineoplastic, Antimetabolite |
|---|
| Disease |
Superficial basal cell carcinomas [DS: H00039] |
|---|
| Comment |
Fluorouracil exerts its anticancer effects through inhibition of thymidylate synthase (TYMS) and misincorporation of its metabolites into RNA and DNA in place of uracil or thymine.
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Metabolism |
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07041 | Antineoplastics - antimetabolic agents |
|
|---|
| Other map |
| map00983 | Drug metabolism - other enzymes |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01B ANTIMETABOLITES
L01BC Pyrimidine analogues
L01BC02 Fluorouracil
D00584 Fluorouracil (JP17/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Dermatological Agents
Dermatological Agents, Other
Warts and Actinic Keratosis Agents
Fluorouracil
D00584 Fluorouracil (JP17/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
422 Antimetabolites
4223 Fluorouracils
D00584 Fluorouracil (JP17/USP/INN)
Target-based classification of drugs [BR:br08310]
Enzymes
Transferases (EC2)
Methyltransferases
TYMS
D00584 Fluorouracil (JP17/USP/INN) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D00584 Fluorouracil
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00584
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D00584
Prodrugs [br08324.html]
D00584
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 9
1 C8y C 20.7957 -18.3013
2 C8y C 19.5791 -19.0057
3 N4x N 22.0068 -19.0057
4 O5x O 20.7843 -16.8981
5 C8x C 19.5791 -20.4030
6 X F 18.3622 -18.3013
7 C8y C 22.0068 -20.4030
8 N4x N 20.7957 -21.1017
9 O5x O 23.2061 -21.1017
BOND 9
1 1 2 1
2 1 3 1
3 1 4 2
4 2 5 2
5 2 6 1
6 3 7 1
7 5 8 1
8 7 9 2
9 7 8 1
|
|---|
